Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
105.90
-5.22 (-4.70%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Monopar Therapeutics Employees
Monopar Therapeutics had 22 employees as of December 31, 2025. The number of employees increased by 6 or 37.50% compared to the previous year.
Employees
22
Change (1Y)
6
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$681,135
Market Cap
709.40M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | 6 | 37.50% | 22 | 0 |
| Dec 31, 2024 | 16 | 6 | 60.00% | 14 | 2 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2022 | 12 | 2 | 20.00% | 11 | 1 |
| Dec 31, 2021 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Neurogene | 131 |
| Aura Biosciences | 113 |
| CytomX Therapeutics | 69 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
| Design Therapeutics | 54 |
MNPR News
- 18 hours ago - Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team - GlobeNewsWire
- 19 days ago - Monopar Therapeutics price target raised to $117 from $104 at BTIG - TheFly
- 20 days ago - Monopar Therapeutics receives Rare Pediatric Disease designation for ALXN1840 - TheFly
- 20 days ago - Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease - GlobeNewsWire
- 20 days ago - Monopar Therapeutics price target raised to $117 from $104 at BTIG - TheFly
- 24 days ago - Monopar Therapeutics announces new FoCus trial analyses - TheFly
- 24 days ago - Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - GlobeNewsWire
- 4 weeks ago - Monopar Therapeutics management to meet virtually with Piper Sandler - TheFly